Holen Sie sich die Stockscreener-App
15.54
0.51%
-0.08
Handel nachbörslich:
15.93
0.39
+2.51%
Schlusskurs vom Vortag:
$15.62
Offen:
$15.66
24-Stunden-Volumen:
1.63M
Relative Volume:
0.69
Marktkapitalisierung:
$2.39B
Einnahmen:
$205.22M
Nettoeinkommen (Verlust:
$-121.24M
KGV:
-19.09
EPS:
-0.8141
Netto-Cashflow:
$-82.81M
1W Leistung:
-5.65%
1M Leistung:
-14.90%
6M Leistung:
+22.75%
1J Leistung:
+105.83%
1-Tages-Spanne:
$15.07
$15.81
1-Wochen-Bereich:
$14.85
$17.98
52-Wochen-Spanne:
$6.255
$20.76
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Firmenname
Adaptive Biotechnologies Corp
Sektor
Branche
Telefon
206-659-0067
Adresse
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
15.54 | 2.40B | 205.22M | -121.24M | -82.81M | -0.8141 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-09-30 | Eingeleitet | Guggenheim | Buy |
| 2025-06-18 | Eingeleitet | Craig Hallum | Buy |
| 2025-03-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Outperform |
| 2022-12-21 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Underperform |
| 2022-06-03 | Eingeleitet | Piper Sandler | Neutral |
| 2022-02-16 | Bestätigt | BTIG Research | Buy |
| 2022-02-16 | Bestätigt | BofA Securities | Buy |
| 2022-02-16 | Bestätigt | Goldman | Neutral |
| 2022-02-16 | Bestätigt | JP Morgan | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-03-03 | Herabstufung | Goldman | Buy → Neutral |
| 2020-10-08 | Fortgesetzt | BTIG Research | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-06-03 | Eingeleitet | Goldman | Buy |
| 2019-07-23 | Eingeleitet | BTIG Research | Buy |
| 2019-07-22 | Eingeleitet | BofA/Merrill | Buy |
| 2019-07-22 | Eingeleitet | Cowen | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Neutral |
| 2019-07-22 | Eingeleitet | Guggenheim | Buy |
| 2019-07-22 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Adaptive Biotechnologies Corp Aktie (ADPT) Neueste Nachrichten
Aug Setups: Can Adaptive Biotechnologies Corporation disrupt its industry2025 Support & Resistance & Momentum Based Trading Ideas - baoquankhu1.vn
Allianz Asset Management GmbH Raises Stock Holdings in Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
Adaptive Biotechnologies (NASDAQ:ADPT) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) CFO Sells 2,145 Shares of Stock - MarketBeat
ADPT: BTIG Raises Price Target Following Analyst Update | ADPT S - GuruFocus
Adaptive Biotechnologies (NASDAQ:ADPT) Price Target Raised to $21.00 - MarketBeat
ADPT: JP Morgan Raises Price Target and Maintains Overweight Rat - GuruFocus
Adaptive Biotechnologies (ADPT) stock swings after earnings as MRD guidance, insider sale draw scrutiny - TechStock²
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2025 Earnings Call Transcript - Insider Monkey
Adeptus Biotechnologies stock price target raised to $22 by BTIG on strong MRD growth By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up on Better-Than-Expected Earnings - MarketBeat
Adeptus Biotechnologies stock price target raised to $22 by BTIG on strong MRD growth - Investing.com UK
Adaptive Biotechnologies Corp (ADPT) Q4 2025 Earnings Call Highl - GuruFocus
Adaptive Biotech (ADPT) Earnings Call Transcript - The Globe and Mail
Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Adaptive Biotechnologies (NASDAQ:ADPT) Releases Quarterly Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
Adaptive Biotechnologies Q4 2025 slides: 55% revenue growth as MRD business expands - Investing.com
Adaptive Biotechnologies (ADPT) Sees Strong Revenue Growth and P - GuruFocus
Earnings call transcript: Adaptive Biotechnologies beats Q4 2025 expectations - Investing.com
Adaptive Biotechnologies (ADPT) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Adaptive Biotechnologies soars after beating Q4 expectations By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies soars after beating Q4 expectations - Investing.com
Adaptive Biotechnologies: Fourth Quarter Financial Highlights - Bitget
Adaptive Biotechnologies: Q4 Earnings Snapshot - KING5.com
Adaptive Biotechnologies earnings beat by $0.09, revenue topped estimates - Investing.com
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Adaptive Biotechnologies (ADPT) falls 24.5% as execs dispose millions of stake - MSN
Biotech Adaptive Biotechnologies lifts 2025 revenue 55%, narrows loss - Stock Titan
Adaptive Biotechnologies earnings on deck: Path to profitability in focus By Investing.com - Investing.com Nigeria
Adaptive Biotechnologies earnings on deck: Path to profitability in focus - Investing.com
Adaptive Biotechnologies CEO Robins sells $2.3 million in stock - Investing.com
Adaptive Biotechnologies CEO Robins sells $2.3 million in stock By Investing.com - Investing.com South Africa
Adaptive Biotechnologies CSO Robins sells $799k in ADPT stock By Investing.com - Investing.com Australia
Adaptive Biotechnologies CSO Robins sells $799k in ADPT stock - Investing.com
Insider Sell: Harlan Robins Sells 42,788 Shares of Adaptive Biot - GuruFocus
Chad Robins Sells 124,998 Shares of Adaptive Biotechnologies Cor - GuruFocus
Adaptive Biotechnologies Executives Sell Shares - TradingView
299,180 Shares in Adaptive Biotechnologies Corporation $ADPT Acquired by Lisanti Capital Growth LLC - MarketBeat
Adaptive Biotechnologies Reports Strong Revenue Growth Amid Strategic Shift - AD HOC NEWS
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences - The Manila Times
Biotech using immune genetics schedules Feb. and March investor webcasts - stocktitan.net
The Analyst Verdict: Adaptive Biotechnologies In The Eyes Of 4 Experts - Benzinga
Guggenheim Raises Price Target for ADPT to $21, Maintains Buy Ra - GuruFocus
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026 - The Manila Times
First Week of March 20th Options Trading For Adaptive Biotechnologies (ADPT) - Nasdaq
Sumitomo Mitsui Trust Group Inc. Trims Holdings in Adaptive Biotechnologies Corporation $ADPT - MarketBeat
Aug Selloffs: Will Adaptive Biotechnologies Corporation stock go up in YEARJuly 2025 Spike Watch & Comprehensive Market Scan Insights - baoquankhu1.vn
Adaptive Biotechnologies Insider Sold Shares Worth $1,411,131, According to a Recent SEC Filing - marketscreener.com
Adaptive Biotechnologies’ Lo Francis sells $1.4m in shares By Investing.com - Investing.com UK
Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) Insider Sells 79,590 Shares of Stock - MarketBeat
Finanzdaten der Adaptive Biotechnologies Corp-Aktie (ADPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):